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Objectives: In the present study, we investigated whether the pH of IP6 could inﬂuence its
anti-tumoral activity in vitro.Methods:PC-3 cells were exposed to IP6 at pH 5, pH 7, and pH
12 and we evaluated the metabolic activity (WST-1 assay), cell proliferation (cell count), cell
cycle distribution (FACS), and mitochondrial depolarization (JC-1 staining) in vitro. Results:
Our results demonstrated that IP6 at pH 5 and pH 12 were more potent at lowering the
metabolic activity of PC-3 cells than IP6 at pH 7. Treatment with IP6 at pH 12 also caused
the greatest inhibition in cellular proliferation and accumulation of PC-3 cells in sub-G1.
Finally, IP6 at pH 12 lead to a reduction in phospho-AKT and phospho-PDK1 and upregu-
lated phospho-ERK. Conclusion: Together, our data strongly suggest that the pH of IP6
effectively modulates its anti-tumoral activity and should be reported in future studies.
Keywords: cell cycle, inositol hexakisphosphate (IP6), metabolic activity, PC-3 cells, phytochemicals
INTRODUCTION
Inositol hexakisphosphate (IP6) is a phytochemical that exhibits
promising anti-tumoral properties against several mouse, rat, and
human cancer cell lines including prostate cancer cells (Vucenik
and Shamsuddin, 2006). IP6 is present in most cereals, legumes,
nuts, oil seed, and soybean (Shamsuddin et al., 1997; Jariwalla,
2001) and is available as an over-the-counter dietary supplement
without any reported toxicity or adverse reactions (Vucenik and
Shamsuddin, 2003).
Effects on tumor cell proliferation, survival, and angiogene-
sis, were documented as being key anti-tumoral properties of
IP6 against prostate cancer cells. Initial studies in PC-3 cells
demonstrated that IP6 inhibits the growth and promotes the dif-
ferentiation of PC-3 cells (Shamsuddin and Yang, 1995). Both
hormone-sensitive (LNCaP) and hormone-refractory (Du145)
cells are sensitive toG1 cell cycle arrest and apoptosis caused by IP6
(Singh et al., 2003; Agarwal et al., 2004). Our group later showed
that hormone-refractory prostate cancer cells (DU145 and PC-3
cells)weremore sensitive to IP6 treatment thanhormone-sensitive
prostate cancer cells (LNCaP and 22rv1 cells; Diallo et al., 2006).
In prostate cancer mice models, IP6 has documented in vivo
anti-tumoral activity (Raina et al., 2008; Gu et al., 2009). Athymic
mice, whose drinking water was supplemented with IP6, exhibited
reduced growth of DU145 xenografts, which was associated with
diminished tumor cell proliferation, increased tumor cell apop-
tosis, and reduced angiogenesis (Singh et al., 2004). In transgenic
adenocarcinoma of the mouse prostate (TRAMP) mice, IP6 sup-
plementation causes the development of a smaller lower urogenital
track (bladder, seminal vesicles, prostate), an increase incidence
of prostate intraepithelial neoplasia (PIN; low-grade and high-
grade), and a decreased incidence of adenocarcinoma (Raina et al.,
2008).
In terms of intracellular signaling, IP6 affects several pathways.
IP6 decreases phospho-AKT (S473) in DU145 cells (Jagadeesh
and Banerjee, 2006). In PC-3 cells, where PI3K signaling is
constitutively activated due to altered expression/functions of
PTEN, IP6 reduces phosphorylation of PI3K p85 (Y458), 3-
phosphoinositide-dependent kinase 1 (PDK1; S241), AKT (S473
and T208), GSK3α/β (S21 and S9), decreases ILK1, and cyclin D1
protein levels (Gu et al., 2009). Altogether, IP6 shows promising
cytotoxic activity against hormone-refractory prostate cancer cells
such as DU145 and PC-3.
As IP6 is generally administered orally through the diet,
typically in drinking water, IP6 must be buffered to a neu-
tral pH before ingestion. IP6 salts are commercially available
in several forms, which when reconstituted in water result in
widely different pH. Typical formulations of the IP6 salt are
basic and when reconstituted in water result in a solution at
pH 12, which is not apt for consumption. The goal of this
study was thus to validate whether the previously documented
anti-tumoral properties of IP6 were modulated by the pH. Our
results demonstrate that IP6 at pH 12 had different effects
than IP6 solutions at pH 7 or pH 5. We conclude that the
effect of pH should be carefully monitored when evaluating the
cytotoxic and anti-cancer properties of IP6 and possibly other
phytochemicals.
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MATERIALS AND METHODS
CELL CULTURE AND REAGENTS
PC-3 and LNCaP cells were obtained from ATCC (Rockville, MD,
USA). Myo-Inositol hexakisphosphate dodecasodium salt (IP6;
US Biological, Swampscott, MA, USA) was diluted in water as
a 100-mM stock solution. The IP6 stock solution was at pH
12. The pH was adjusted to pH 5 or pH 7 by addition of 1N
hydrochloric acid (HCl). It required 6.4 and 10.9ml of 1N HCl
to buffer 100ml of 100mM IP6 pH 12 to pH 7 and pH 5, respec-
tively. Antibodies recognizing phospho-AKT (S473; cat# 9271),
phospho-PDK1 (S241; 3438) and phospho-ERK (T202/Y204; cat#
9106L) were obtained from Cell Signaling (Danvers, MA, USA).
Antibodies detecting PARP full-length (sc7150), PARP 85 kDa
(cat# 9541), PARP 25 kDa (cat# 32064) were obtained from Santa
Cruz Biotechnology (Santa Cruz, CA, USA), Cell Signaling and
Abcam (Cambridge, MA, USA), respectively. The anti-Ran anti-
body (sc1146) and the horseradish peroxidase-conjugated sec-
ondary antibodies were obtained from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA). The antibodies recognizing actin
(ab-6278) and GAPDH (ab-9485) were obtained from Abcam
(Cambridge, MA, USA).
WST-1 METABOLIC ASSAY
The WST-1 metabolic assay was done as previously described by
our group (Diallo et al., 2006, 2008). Brieﬂy, PC-3 cells were
plated at 200,000 cells/ml in 96-well plates in a ﬁnal volume of
100μl/well. After a 24-h incubationwithH2Oor IP6 at the various
pH and at the indicated concentrations, 20μl of WST-1 reagent
(Roche Diagnostics, Indianapolis, IN, USA) was added and the
plates were incubated for 24 h. WST-1 signal was measured at
450 nm with reference wavelength at 655 nm.
CELLULAR PROLIFERATION
PC-3 cells were plated at 15,000 cells/ml in 6-well plates, allowed
to adhere overnight and then treated with 2mM IP6 at pH 5,
pH 7, or pH 12 or the equivalent volumes of pH-adjusted H2O
controls over a period of 72 h. At indicated times cells were
trypsinized, combined with non-adherent cells and counted using
a cell counter (Casy, Roche Innovatis, Germany).
CELL CYCLE DISTRIBUTION ANALYSIS
PC-3 cells were plated at 200,000 cells/ml in 6-well plates. PC-3
cells were exposed to H2O or 2mM IP6 at the various pH for 8,
24, 48, and 72 h. Adherent cells were trypsinized, combined with
non-adherent cells, stained with propidium iodide (PI), and ana-
lyzed by ﬂow cytometry. All experiments were repeated at least
three times.
WESTERN BLOT ANALYSIS
Western blots were performed as previously described by our
group (Diallo et al., 2006, 2008). Signal was developed with
enhanced chemiluminescence (ECL) substrate (Amersham Life
Sciences Inc., Arlington Heights, IL, USA).
MITOCHONDRIAL DEPOLARIZATION ASSAY
The mitochondrial assay was done as previously described by our
group (Diallo et al., 2008). Brieﬂy,PC-3 cells were plated at 200,000
cells/ml in 6-well plates. PC-3 cells were incubated with a ﬂuores-
cent cationic dye (JC-1 10μg/ml) for 15min. Adherent cells were
trypsinized, combined with non-adherent cells, and analyzed by
ﬂow cytometry. The fold change representing depolarized mito-
chondria (green-shift in JC-1 ﬂuorescence) was calculated relative
to mock-treated control.
STATISTICAL ANALYSES
Data are expressed as mean± SD. Comparisons between the IP6
or H2O controls at the various pH were performed using one-way
ANOVA followed by post hoc Tukey tests. Statistical analyses were
performed using SPSS version 16.0 (SPSS, Inc., Chicago, IL, USA).
For all statistical analyses, P values <0.05 were considered to be
statistically signiﬁcant.
RESULTS
IP6 DIMINISHES THE METABOLIC ACTIVITY OF PC-3 CELLS
We ﬁrst evaluated the effect of the pH of IP6 on the metabolic
activity of PC-3 cells. The cells were treated with either increasing
doses of IP6 at pH 5, pH 7, and pH 12 or the corresponding vol-
umes of H2O also at pH 5, pH 7, and pH 12. IP6 at pH 5 (2.5, 4,
and 5mM) and pH 12 (4 and 5mM) induced a statistically signif-
icant reduction in the metabolic activity of PC-3 cells (Figure 1A)
compared to the buffered H2O (Figure 1B; P < 0.05, ANOVA).
Statistically signiﬁcant differences compared to the H2O controls
were not observed with IP6 at pH 7, independently of the concen-
tration tested. With regards to pH, the IP6 at pH 12 and at pH 5
had the strongest inhibitory potential. At the highest doses tested,
IP6 at pH 5 reduced the metabolic rate by 88.0% (P< 0.001, com-
pared to H2O at pH 5, ANOVA), and, at similar concentration,
IP6 at pH 12 decreased the metabolic rate by 78.6% (P< 0.001,
compared to H2O at pH 12, ANOVA). Comparatively, the highest
dose of IP6 solution at pH 7 only reduced the metabolic activity
by 26.1% (P= 0.627, compared to H2O at pH 7, ANOVA). More-
over, the lowest concentration at which IP6 at pH 5 and pH 12
statistically signiﬁcantly reduced the metabolic rate was 2.5mM
(P= 0.001, compared to H2O at pH 5 and P = 0.012, compared
to H2O at pH 12, respectively, ANOVA).
We then evaluated the IC50 and IC75 for the various IP6 solu-
tions.Due to the absence of a signiﬁcant reduction in themetabolic
activity following treatment with IP6 at pH 7 no IC50 could be
calculated. The IC50 for IP6 at pH 5 was 2.39± 0.19mM and
2.97± 0.45 for IP6 at pH 12 (Table 1). Together, these results
demonstrate that IP6 solutions at different pH have divergent
effect on the metabolic activity of PC-3 cells.
Finally, we inquired whether the addition of small volumes
(60μl) of IP6or bufferedH2O solutions could signiﬁcantly change
the pH of the culture media (Figure A1 in Appendix). Our analy-
ses showed that, at time of administration (t – 0 h) and compared
to water controls, the IP6 at pH 12 and at pH 5 signiﬁcantly mod-
ulated the pH of the culture media (P < 0.001, ANOVA). These
changes in pH were however absent after 24 h of treatment.
IP6 AT pH 12 HAS THE STRONGEST ANTI-PROLIFERATION EFFECT ON
PC-3 CELLS
We next evaluated the impact of pH on the anti-proliferation
action of IP6. As previously described, PC-3 cells were treated
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FIGURE 1 | IP6 decreases the metabolic activity and cellular
proliferation of PC-3 cell lines. (A,B) PC-3 cells were treated for 24 h with
increasing concentration of (A) IP6 at pH 5, pH 7, or pH 12 or (B)
corresponding volume of H2O at pH 5, pH 7, or pH 12. Metabolic activity was
measured using theWST-1 assay and calculated relative to controls. Data
represents the average of three experiments done in triplicate. Errors bars
represent standard error of the mean. Statistically signiﬁcant differences
compared to the corresponding water control. (C,D) PC-3 cells were treated
with (C) 2mM IP6 at pH 5, pH 7, or pH 12 or (D) the corresponding volumes
of H2O at pH 5, pH 7, and pH 12. Cellular proliferation was examined by cell
count at 24, 48, and 72 h. Data represents average of three experiments.
Errors bars represent standard error of the mean. Statistically signiﬁcant
differences compared to the corresponding water control where *P<0.05
and **P <0.001 (ANOVA).
with 2mM IP6 solutions or with the corresponding volumes of
buffered H2O. We chose the 2-mM IP6 dose in line with other
studies by our group (Diallo et al., 2008) and others (Gu et al.,
2009; Roy et al., 2009). Following a 72-h stimulation, IP6 at pH
12 signiﬁcantly reduced cell number by 60.4% (P = 0.001, com-
pared to H2O at pH 12, ANOVA), whereas a treatment with IP6 at
pH 5 reduced the proliferation rate by 46.9% (P = 0.0029, com-
pared to H2O at pH 5, ANOVA), and by 46.6% for the IP6 at pH
7 (P = 0.015, compared to H2O at pH 7, ANOVA; Figures 1C,D).
Together, these results suggest that IP6 at pH 12 had the strongest
anti-proliferation potential.
IP6 AT pH 12 INCREASES THE PROPORTION OF SUB-G1 PC-3 CELLS
We then assessed whether the reduction in metabolic activity and
in cellular proliferation (Figure 1) was related to an increase in
cell death. PC-3 cells were treated as previously described with
either 2mM IP6 or H2O controls over a period of 72 h. Adherent
and non-adherent cells were analyzed by FACS, following staining
with PI for 15min. We observed that, compared to H2O, only the
Table 1 | IC50 and IC75 of IP6 at varying pH.
[] at *IC50 [] at *IC75
IP6 pH 5 2.39±0.19 3.96±0.60
IP6 pH 7 N/A N/A
IP6 pH 12 2.97±0.45 4.04±0.64
N/A, non-applicable.
*Concentration in millimolar.
IP6 solution at pH 12 caused a statistically signiﬁcant increase in
sub-G1 cells at 8 h (5.21 vs 0.71%, P < 0.001, ANOVA) and at 24 h
(3.96 vs 0.59%,P < 0.001,ANOVA;Figure 2A). At 8 h, the increase
in sub-G1 cells was also associated with a decrease in PC-3 cells
in G2/M phase (Table 2). No statistically signiﬁcant induction of
sub-G1 PC-3 cells were observed following treatment with IP6 at
pH 5 or at pH 7 or with the corresponding H2O controls (Table A1
in Appendix).
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FIGURE 2 | IP6 at pH 12 leads to an increase in sub-G1 PC-3 cells.
(A) PC-3 cells were stained with PI after a 24-h treatment with either
2mM IP6 at pH 5, pH 7, or pH 12 or the corresponding volumes of
H2O at pH 5, pH 7, and pH 12. The percentage of cells in G1, S, G2/M, and
sub-G1 phases was determined by FACS. MG132 served as a control to
induce cellular apoptosis. Data is represented as the relative fold change
compared to non-treated control. Average of three experiments done in
triplicate. Errors bars represent standard error of the mean. (B)Whole-cell
extracts were prepared following a 24-h treatment as previously described.
Western blotting was used to probe for PARP and cleaved-PARP (85 and
25 kDa). RAN expression was used as a loading control. Blot is representative
of three independent experiments.
IP6 AT pH 12 MODULATES THE LEVEL OF PARP-1
By Western blot, we then studied whether Poly (ADP-ribose)
polymerase 1 (PARP-1), was cleaved following IP6 treatment, as
an indication of apoptosis induction. Following a 24-h stimu-
lation with 2mM IP6 at pH 12, we observed a most complete
disappearance of full-length PARP-1 (Figure 2B). Surprisingly,
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this reduction in PARP-1 expression was not associated with the
appearance of the cleaved-PARP 85 and 25 kDa fragments as
observed with the MG132 positive control stimulation. We did
not detect any reduced expressionof full-lengthPARP-1orPARP-1
cleavage following treatment with IP6 at pH 5 or at pH 7.
We also noticed that the effects observed by IP6 at different
pH varied according to the cell line used in the experiment.
Using the hormone-sensitive LNCaP cell line treated with the
various IP6 solutions, we observed an elevated expression of
the cleaved-PARP-1 25 kDa fragment following exposure to IP6,
something thatwas not observedwith the PC-3 cell line (FigureA2
in Appendix).
IP6 DOES NOT CAUSE MITOCHONDRIAL DEPOLARIZATION
The reduction in metabolic activity, cellular proliferation com-
bined with the abundance of sub-G1 PC-3 cells lead us to
Table 2 | Cell cycle distribution* after 8 h of IP6 treatment.
G1 S G2/M Sub-G1
Ctrl 53.56±2.01 9.23±1.43 25.96±0.86 0.51±0.09
MG132 54.10±2.55 7.86±1.13 27.76±4.33 0.59±0.08
H2O pH 5 53.18±2.15 11.00±2.60 25.67±1.33 0.45±0.09
H2O pH 7 53.53±1.91 11.23±2.78 25.72±1.39 0.41±0.08
H2O pH 12 53.15±2.53 10.10±1.75 25.72±1.31 0.71±0.25
IP6 pH 5 53.95±1.85 10.88±2.70 25.80±0.86 0.61±0.10
IP6 pH 7 53.63±2.62 10.41±1.48 26.03±0.58 0.68±0.13
IP6 pH 12 50.24±3.25 8.85±1.80 22.13±0.97 5.21±0.88
Results highlighted and in bold are statistically signiﬁcantly different.
Compared to the corresponding water control.
*Cell percentage in each phase quantiﬁed by FACS following PI staining.
FIGURE 3 | IP6 does not impact mitochondrial depolarization. PC-3 cells
were treated with either 2mM IP6 at pH 5, pH 7, or pH 12 or the
corresponding volumes of H2O at pH 5, pH 7, and pH 12 for after 4, 8, 24, and
48 h. In the last 15min prior to analysis, cells were stained with JC-1 and
mitochondrial depolarization was assessed by FACS. MG132 served as a
control to induce cellular apoptosis. Data is represented as the relative fold
change compared to non-treated control. Average of three experiments done
in triplicate. Errors bars represent standard error of the mean.
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investigate mitochondrial depolarization or mitochondrial outer
membrane permeation (MOMP), another event associate with
apoptotic cell death. Similar to PARP cleavage (Kaufmann et al.,
1993),mitochondrial depolarization is an early event of apoptosis,
which is associated with the release of cytochrome c (Heiskanen
et al., 1999). Mitochondrial depolarization can be quantiﬁed by a
shift from red to green following JC-1 staining. Our results illus-
trate that, compared to H2O controls, there was no statistically
signiﬁcant induction of mitochondrial depolarization by IP6 at
the various pH studied (Figure 3). Together, these results suggest
that IP6 promotes the accumulation of sub-G1 PC-3 cells and the
reduced expression of PARP.However, this increase in sub-G1 cells
was not associated with the appearance of cleaved-PARP or mito-
chondrial depolarization, two factors typically associated with an
apoptotic cell death.
IP6 AT pH 12 MODULATES INTRACELLULAR SIGNALIZATION
Finally, we then evaluated whether the pH of the IP6 solution
could differentially affect the phosphorylation status of intracel-
lular effectors documented to be modulated by IP6. We detected
a clear decrease in the phosphorylation status of AKT (S473) and
PDK1 (S241) following treatment with IP6 at pH 12 (Figure 4A).
Again, these variations were not observed with the IP6 at pH 5
or at pH 7. Conversely, we observed an induced expression of
phospho-ERK (T202/Y204) with the IP6 at pH 12. The expression
of phospho-ERKwas also apparent following stimulationwith IP6
at pH 7, albeit to a smaller extent (Figure 4B). Overall, our results
demonstrate that the pHof the IP6 solution directly inﬂuenced the
IP6 actions on cellular metabolism, proliferation, and cell cycling,
as well as intracellular signaling.
DISCUSSION
Numerous publications discuss the anti-cancer properties of IP6
in in vitro and in vivo prostate cancer models (reviewed in
Vucenik and Shamsuddin, 2006). There are several cellular path-
ways affected by IP6 and the molecular machinery modulated
following IP6 treatment is being further characterized. As IP6 is
orally administered in vivo, the IP6 solution must accordingly be
edible. However, when the often-used dodecasodium IP6 salt is
reconstituted in aqueous solution, the resulting solution is at pH
12, which is not ﬁt for consumption. In this study, we questioned
whether the pH of the ingested IP6 solution could inﬂuence the
previously documented cytotoxic properties of IP6.
The results presented in this study conﬁrmed that, compared
to pH-adjusted control H2O solutions, IP6 at any pH reduced
the metabolic rate and the proliferation of hormone-refractory
PC-3 cells. However, it was the IP6 solutions at pH 5 and pH
12 that offered the most signiﬁcant inhibitory potential on the
metabolic rate of PC-3 cells and the IP6 at pH 12 that most signif-
icantly in vitro reduced cellular proliferation. Furthermore, when
we investigated the phosphorylation status of key signaling mol-
ecules described to be regulated by IP6, we observed that, again,
only the IP6 solution at pH 12 diminished the phosphorylation of
key signaling molecules. Comparatively, the IP6 at pH 5 and pH 7
did not modulate the phosphorylation of AKT or PDK1 and had a
weak induction of phospho-ERK compared to IP6 at pH 12. These
results contrast with recently published data showing a signiﬁcant
FIGURE 4 | IP6 at pH 12 modulates intracellular signaling. PC-3 cells
were treated for 24 h with either 2mM IP6 at pH 5, pH 7, or pH 12 or the
corresponding volumes of H2O at pH 5, pH 7, and pH 12.Whole-cell
extracts were prepared andWestern blotting was used to probe for (A)
phospho-AKT (Ser 473), AKT, phospho-PDK1 (Ser 241) and PDK and for (B)
phospho-ERK. MG132 served as a control to induce cellular apoptosis. Blot
is representative of three independent experiments. GAPDH and actin
expression were used as a loading control. Dashed boxes signal indicate
decreased protein levels relative to water controls.
effect of IP6 buffered at pH 7.4 on the proliferation of PC-3 cells as
well as on the phosphorylation status of AKT and ERK (Gu et al.,
2010). The impact of pH on the regulatory properties of IP6 on
other signaling pathways should be further assessed as our results
clearly illustrate the impact of pH on the IP6 properties.
The intriguing results observed in our study concerns accumu-
lation of sub-G1 PC-3 cells following treatment with IP6 at pH
12. Whereas short-lived and low level MOMP is observed follow-
ing treatment with both water pH 12 and IP6 pH 12, only IP6
pH 12 leads to increased cytotoxicity, acute sub-G1 cell accumu-
lation, and reduced cell growth. We must therefore conclude that
the MOMP observed in both cases is not linked with apoptosis
but may instead be an artifact induced by basic pH. The obser-
vation of sub-G1 cells only in the IP6 pH 12-treated cells (and
not at neutral or acidic pH) is nonetheless intriguing. To explain
this phenomenon, we need to consider the fact that the pI/cell
cycle assay sub-G1 peak actually measures cells in which DNA has
been fragmented and lost from the cells due to the ﬁxation proce-
dure. While DNA fragmentation occurs at late stages of apoptosis
(e.g., after 24 h with MG132) it can also occur following exten-
sive DNA-damage via double-strand (DS) breaks. Note that the
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IP6 sub-G1 is maximal at 8 h then progressively decreases. This
could suggest that DNA DS breaks are being induced by IP6 pH
12 early on then progressively repaired. We would further predict
that such DS breaks would occur preferentially in the G2/M phase
of the cell cycle, as the fraction of cells in this phase inversely cor-
relates with the sub-G1 peak. This idea is particularly interesting
considering that in the literature, endogenous IP6 normally found
in cells (which should be at ∼pH 7 as opposed to pH 12) has
been found to stimulate non-homologous end-joining (NHEJ)
by binding Ku70/80. It is tempting to speculate that IP6 at pH 12
inhibits rather that stimulates repair via NHEJ, leading to accumu-
lation of DS breaks in cells undergoing G2/M transition. As the
pH/ionic balance eventually re-equilibrates following IP6 pH 12
treatment (see Figures A1A,B in Appendix), NHEJ repair would
then resume leading to progressively fewer DS breaks an conse-
quently fewer sub-G1 cells over time and resumed progression
through G2/M or cell death through a non-apoptotic mechanism.
However, since we also observe decreased growth rates in cells
treated with IP6 pH 5 without accumulation of cells in sub-G1,
more experiments are needed to precisely characterize how IP6
leads to reduced cell growth rates/and death in a pH-dependent
fashion.
One mechanism that has been proposed to mediate the chemo-
preventive abilities of IP6 activity is through its role as an anti-
oxidant. The negatively charged phosphates in position 1, 2, and
3 constitute a unique (axial–equatorialaxial) conformation that
confers anti-oxidant properties to IP6 by chelating Fe3+ and pre-
venting Fe3+-catalyzed hydroxyl radical formation (Graf et al.,
1987;Hawkins et al., 1993; Spiers et al., 1996). IP6-mediated chela-
tion of other metals such as zinc, calcium, and magnesium has
also been proposed to play a role due to the potential role of these
divalent cations in cell proliferation (Thompson and Zhang, 1991;
Jariwalla, 1999;Urbano et al., 2000). As wewould expect that at pH
12, the chelating potential of IP6would be greater than at lower pH
(because of an excess of free H+ ions), perhaps basic conditions
favor metal chelating properties of IP6. Chelating properties of
IP6, could also be expected to impact cellular processes such as
calcium-mediated signaling and clathrin-mediated receptor endo-
cytosis, which has been notably found to be inhibited by IP6 (Zi
et al., 2000).
Since the pH can change drastically as the molecule travels
through the gastro-intestinal tract, our ﬁndings have implications
for in vivo use of IP6,which has largely been via oral routes thus far.
In addition to the fact that mM concentrations of IP6 are required
to elicit anti-cancer activity, this may argue for further evaluating
the activity of basic-pH buffered IP6 formulations by intravenous
injection. To this end, while the concentrations required for IP6-
mediated anti-tumor activity are certainly high, it should be noted
that glucose, which is of similar chemical composition, is typi-
cally present in the blood at concentrations of∼5mM (Lam et al.,
2005). In addition, some clinically approved HDAC inhibitors,
such as sodium butyrate and valproic acid for example, are also
active in the mM range when used in vitro (Kuefer et al., 2004; Xia
et al., 2006).
In conclusion, our work demonstrates that the pH of the IP6
solution must be taken in consideration when evaluating the
anti-tumoral properties of this phytochemical. We demonstrate
signiﬁcant differences in the activity of IP6 depending on its pH
on the metabolic activity, cell proliferation, and cell death of PC-3
cells.
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APPENDIX
FIGUREA1 | pH variations of the culture media after IP6 or water
treatment. PC-3 cells were plated at 200,000 cells/ml in 6-well plates in a
ﬁnal volume of 3ml of medium/well. The culture media consists in RPMI
1640 complemented with 10% FCS, gentamicin (50μg/ml), and
amphotericin B (250 ng/ml; Gibco, Carlsbad, CA, USA). PC-3 cells were
treated with either 2mM IP6 at pH 5, pH 7, or pH 12 or the corresponding
volumes of H2O at pH 5, pH 7, and pH 12. In parallel, culture media without
PC-3 cells were supplemented with similar volumes of 2mM IP6 or H2O.
The pH was measured immediately after stimulation [0 h, (A)] or after 24 h
(B) of treatment using a pH-meter (Corning pH meter 340, Corning, NY,
USA). Data represents average of three experiments. Errors bars represent
SD.
FIGUREA2 | LNCaP cells react differently than PC-3 cells to IP6
treatment at various pH. LNCaP cells were treated for 24 h with either
2mM IP6 at pH 5, pH 7, or pH 12 or the corresponding volumes of H2O at
pH 5, pH 7, and pH 12.Whole-cell extracts were prepared andWestern
blotting was used to probe for PARP, cleaved-PARP (25 kDa). Blot is
representative of three independent experiments. Actin expression was
used as a loading control.
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FIGUREA3 | Phosphorylation status of several kinases in LNCaP cells
following IP6 treatment using Proteome Profiler membranes. LNCaP
cells were treated for 24 h with either 2mM IP6 at pH 5, pH 7, or pH 12 or
the corresponding volumes of H2O at pH 5, pH 7, and pH 12.Whole-cell
extracts were prepared according to the manufacturer’s protocol and
hybridized to the proteome proﬁler membranes (RnD Systems).
Densitometry was performed with the Quantity One software (BioRad)
using the positive control dots (top left, bottom left, and top right corners)
in the qualitative expression ratio. Protein proﬁler membranes and
corresponding densitometry for: (A,B) pH 5, (C,D) pH 7, (E,F) pH 12. Note
that the signal was relatively similar for the three conditions (pH 5, pH 7,
and pH 12) with few kinase phosphorylations detected. However, we did
observe an increase in the phosphorylation of AKT2 with the IP6 pH 12
treatment.
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Table A1 | Cell cycle distribution* following IP6 treatment.
G1 G2/M
8h 24h 48h 72h 8h 24h 48h 72h
Ctrl 53.56±2.0 55.11±2.3 58.15±4.8 56.07±3.4 25.96±0.9 25.28±4.0 24.80±4.0 27.14±4.0
MG132 54.10±2.6 63.22±3.5 55.33±6.6 33.12±3.5 27.76±4.3 14.15±2.6 10.70±3.2 11.62±3.8
H2O pH 5 53.18±2.2 55.06±2.3 59.76±4.6 57.35±2.9 25.67±1.3 24.17±2.9 24.31±3.1 27.04±2.2
H2O pH 7 53.53±1.9 54.42±2.1 58.29±4.8 55.01±3.0 25.72±1.4 25.18±3.8 23.78±4.0 28.46±3.5
H2O pH 12 53.15±2.5 52.22±2.0 56.64±5.3 55.73±2.8 25.72±1.3 26.66±3.9 24.83±3.6 27.35±3.7
IP6 pH 5 53.95±1.8 56.71±2.2 58.13±4.0 56.89±3.1 25.80±0.9 23.94±3.1 24.33±2.7 28.43±2.1
IP6 pH 7 53.63±2.6 57.72±2.8 58.70±5.1 56.14±2.6 26.03±0.6 24.03±3.5 25.11±3.7 26.03±2.5
IP6 pH 12 50.24±3.2 55.29±2.8 56.60±3.5 52.48±2.7 22.13±1.0 22.29±1.9 26.38±3.3 26.69±3.1
S Sub-G1
8h 24h 48h 72h 8h 24h 48h 72h
Ctrl 9.23±1.4 7.79±0.8 6.73±0.7 7.89±1.7 0.51±0.1 0.56±0.1 0.71±0.2 0.52±0.1
MG132 7.86±1.1 6.00±0.6 5.19±0.9 5.82±1.0 0.59±0.1 2.37±0.7 20.28±3.4 40.13±7.5
H2O pH 5 11.00±2.6 8.15±0.3 6.99±0.8 8.23±1.7 0.45±0.1 0.74±0.2 0.58±0.1 0.34±0.1
H2O pH 7 11.23±2.8 8.30±0.7 7.10±1.6 8.44±2.1 0.41±0.1 0.78±0.1 0.65±0.1 0.37±0.0
H2O pH 12 10.10±1.7 8.70±0.8 6.72±1.0 7.24±1.8 0.71±0.2 0.59±0.2 0.73±0.1 0.35±0.0
IP6 pH 5 10.88±2.7 7.64±1.0 8.10±1.3 8.81±2.4 0.61±0.1 1.33±0.2 0.87±0.2 0.53±0.2
IP6 pH 7 10.41±1.5 7.92±0.9 7.51±1.0 8.36±1.8 0.68±0.1 1.41±0.3 0.92±0.1 0.50±0.0
IP6 pH 12 8.85±1.8 8.29±1.0 7.71±1.1 8.32±1.8 5.21±0.9 3.96±0.8 2.63±0.5 1.11±0.2
Results highlighted and in bold are statistically signiﬁcantly different compared to the corresponding water control.
*Cell percentage in each phase quantiﬁed by FACS following PI staining.
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